UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000007662
Receipt No. R000009031
Scientific Title Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy
Date of disclosure of the study information 2012/04/09
Last modified on 2016/07/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy
Acronym Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer
Scientific Title Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy
Scientific Title:Acronym Evaluation of the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer
Region
Japan

Condition
Condition Colorectal Cancer
Classification by specialty
Gastroenterology Hematology and clinical oncology Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy of XELOX(L-OHP: 100mg/m2)+Bevacizumab for patient with metastatic or recurrent Colorectal Cancer as first-line chemotherapy
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase II

Assessment
Primary outcomes Response Rate
Key secondary outcomes Progression free survival, Overall Survival,
1-year survival rate, Disease control rate, Dose Intensity, Safety

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Capecitabine plus oxaliplatin(L-OHP: 100mg/m2) with bevacizumab
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Histologically proved colon cancer(adenocarcinoma)
2) Advanced or recurrent colorectal cancer that is not amenable to curative resection,and first line chemotherapy
3) >=20years-old
4) ECOG performance status 1-2
5) With measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
6) Life expectancy greater than or equal to 3 months
7) Patient of possible oral ingestion
8) Adequate organ function
9) Patient who doesn't have cerebral metastasis
10)Written informed consent
11) Other conditions suitable for this study
Key exclusion criteria 1) History of the serious hypersensitivity for Fluorouracil , Levofolinate calcium,platinum or bevacizumab
2) History of adverse events related to DPD loss
3) Active multiple Primary cancer within 5 years
4) Uncontrolled diarrhea
5) Any surgical treatments oncluding skin-open biopsy,trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week
6) Complication of cerebrovascular disease or symptoms within 1 years
7) Administering antithrombotic drug within 10 days before enrollment
8) Need tobadministrate or having anti-plateles therapy(including Methotrexate aspirin and NSAIDS)
9) Evidence of bleeding diathesis or
coagulopathy
10) Symptom of colorectal obstruction
11) uncontrolled complication of peptic ulcer
12) Current or previous (within the last 1 year) history of GI perforation
13) Renal failure to be treated,2+ or higher proteinuria within 2 weeks prior to entry
14) Uncontrolled Hypertension
15) Uncontrolled Infection
16) Pregnant women,possibly pregnant women,wishing to become pregnant,and nursing mothers
17) Man who doesn't practice birth control
18) Other conditions not suitable for this study
Target sample size 52

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Taro Satoh
Organization Osaka University Hospital
Division name Department of Frontier Science for Gastrointestinal Cancers and Chemotherapy
Zip code
Address 2-2 Yamadaoka Suita City Osaka
TEL 06-6879-3251
Email taroh@cfs.med.osaka-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Masataka Ikeda Tsunekazu Mizushima
Organization Osaka University Graduate School of Medicine
Division name Department of Surgery
Zip code
Address 2-2 Yamadaoka, Suita, Osaka 565-0871,Japan
TEL 06-6879-3251
Homepage URL
Email tmizushima@gesurg.med.osaka-u.ac.jp

Sponsor
Institute Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 04 Month 09 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2012 Year 04 Month 02 Day
Date of IRB
Anticipated trial start date
2012 Year 04 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2012 Year 04 Month 04 Day
Last modified on
2016 Year 07 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009031

Research Plan
Registered date File name
2016/07/06 治癒切除不能・進行再発大腸癌における1次治療としての XELOX(L-OHP 100mgm2)+ベバシズマブ.zip

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.